Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

DEA Increases Production Quota to Manufacture Medication to Treat Attention Deficit Disorder

Posted 10/1/2023

To address shortages of methylphenidate HCl extended-release tablets, a common drug used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy, DEA will raise the amount that may be produced.

On Sept. 29, DEA Administrator Anne Milgram issued an order that revises the 2023 Aggregate Production Quota for methylphenidate (for sale) from 41,800 kilograms to 53,283 kilograms. View a copy of the final order.

This follows notification from the FDA that the medication was on the drug shortage list and addresses the manufacture of a drug that is life-supporting, life-sustaining, or intended for the treatment or prevention of debilitating diseases.

Back to all news

Sponsor Spotlight

COMPASS Pathways

COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more

All Sponsors